Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 7/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31160996 | 0.92 | HDAC1 (0.38) | HDAC1HDAC6MAPK8MAPTMEN1 | |
| SCHEMBL321669 | 0.90 | HDAC1 (0.40) | HDAC1HDAC6MAPK8MAPTMEN1 | |
| SCHEMBL31160912 | 0.87 | HDAC1 (0.39) | HDAC1HDAC6MAPK8MAPTMEN1 | |
| SCHEMBL31161039 | 0.82 | SMN1; SMN2 (0.36) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL14916426 | 0.81 | MAPT (0.39) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL14917190 | 0.78 | NPC1 (0.40) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL31161068 | 0.74 | ALDH1A1 (0.32) | POLBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL321863 | 0.73 | CA12 (0.41) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL14916577 | 0.73 | BRD4 (0.40) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL16340821 | 0.72 | HTT (0.39) | MAPTMEN1KMT2AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688756-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206345-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | TSPO 390/4885HDAC1 1680/4885HDAC6 1296/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | TSPO 1173/4885HDAC1 932/4885HDAC6 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.